Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

DexCom, Inc. DXCM

Healthcare  —  Medical Devices
86.62 (0.85) (0.97%) as of 25 Sep
Market cap
$33.0B
P/E
33.4×
S&P 500 Member Cash Flow Champion (3y) Insider Buys (last 12m)
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

DexCom, Inc. (DXCM) Business Profile

Updated before January 2025

Company Overview

DexCom, Inc. (DXCM) is a leading medical technology company specializing in continuous glucose monitoring (CGM) systems for diabetes management. Founded in 1999 and headquartered in San Diego, California, DexCom has revolutionized the way people with diabetes monitor their glucose levels. The company was established by Scott Glenn and John Burd, with the mission of improving the quality of life for individuals living with diabetes through innovative technology. Over the years, DexCom has grown into a global leader in the CGM market, with its products widely recognized for their accuracy, ease of use, and integration with other diabetes management tools.

DexCom’s leadership team is composed of seasoned professionals with extensive experience in the healthcare and technology sectors. Kevin Sayer serves as the Chairman, President, and Chief Executive Officer, bringing a wealth of expertise in medical devices and corporate strategy. Under his leadership, DexCom has expanded its product portfolio and strengthened its position in the global market. Other key executives include Quentin Blackford, the Chief Operating Officer, and Jereme Sylvain, the Chief Financial Officer, both of whom play critical roles in driving the company’s operational and financial success.

Core Business Segments

DexCom’s core business revolves around the development, manufacturing, and distribution of CGM systems. These systems are designed to provide real-time glucose readings, enabling individuals with diabetes to make informed decisions about their health. The company’s product portfolio can be categorized into the following segments:

Continuous Glucose Monitoring Systems

  1. DexCom G6: The DexCom G6 is one of the company’s flagship products, offering real-time glucose monitoring without the need for fingersticks. It features a small, wearable sensor that measures glucose levels and transmits data to a compatible smart device or receiver. The G6 system is known for its accuracy, ease of use, and ability to integrate with insulin pumps and other diabetes management tools.

  2. DexCom G7: The DexCom G7, the company’s latest innovation, builds on the success of the G6 with a smaller, more discreet sensor and improved performance. It offers faster warm-up times, enhanced accuracy, and a more user-friendly design, making it a preferred choice for many users.

Software and Data Analytics

DexCom also provides software solutions and data analytics tools to enhance the user experience and support healthcare providers. These include:

  • DexCom Clarity: A cloud-based platform that allows users and healthcare professionals to track glucose trends, generate reports, and make data-driven decisions.
  • Mobile Apps: DexCom’s mobile apps enable users to monitor their glucose levels on their smartphones, set alerts, and share data with caregivers or healthcare providers.

Integration with Third-Party Devices

DexCom’s CGM systems are designed to integrate seamlessly with other diabetes management devices, such as insulin pumps and automated insulin delivery systems. This interoperability enhances the overall effectiveness of diabetes care and provides users with a comprehensive solution.

Business Model

DexCom operates on a subscription-based business model, generating revenue through the sale of CGM systems, sensors, and related accessories. The company’s primary revenue streams include:

  1. Sensor Sales: The disposable sensors used in DexCom’s CGM systems are a significant source of recurring revenue. Users typically replace sensors every 10 to 14 days, creating a steady demand for these products.
  2. Transmitters and Receivers: DexCom also generates revenue from the sale of transmitters and receivers, which are essential components of its CGM systems.
  3. Software and Services: The company offers subscription-based software solutions, such as DexCom Clarity, which provide additional value to users and healthcare providers.

DexCom’s business model emphasizes innovation, customer satisfaction, and long-term relationships with users. By continuously improving its products and expanding its ecosystem, the company aims to maintain its leadership position in the CGM market.

Strategic Direction

DexCom’s strategic direction focuses on expanding its market presence, driving innovation, and promoting sustainability. Key initiatives include:

  1. Market Expansion: DexCom is actively working to increase its global footprint by entering new markets and expanding its distribution network. The company is particularly focused on emerging markets, where the prevalence of diabetes is rising rapidly.
  2. Product Innovation: DexCom continues to invest heavily in research and development to enhance its existing products and develop new solutions. The launch of the DexCom G7 is a testament to the company’s commitment to innovation.
  3. Sustainability Goals: DexCom is committed to reducing its environmental impact by adopting sustainable practices in its manufacturing processes and supply chain operations.
  4. Broadening Applications: The company is exploring opportunities to expand the use of its CGM technology beyond diabetes management, such as in weight management and general health monitoring.

Competitive Landscape

DexCom operates in a highly competitive market, facing competition from both established players and emerging startups. Key competitors include:

  1. Abbott Laboratories: Abbott’s FreeStyle Libre system is a major competitor to DexCom’s CGM products. The FreeStyle Libre is known for its affordability and ease of use, making it a popular choice among users.
  2. Medtronic: Medtronic offers integrated diabetes management solutions, including CGM systems and insulin pumps. The company’s MiniMed series competes directly with DexCom’s products.
  3. Senseonics: Senseonics is a smaller player in the CGM market, offering the Eversense system, which features an implantable sensor with a longer lifespan.

Despite the competition, DexCom’s focus on innovation, accuracy, and user experience has helped it maintain a strong position in the market.

Risk Factors

DexCom faces several risks that could impact its business operations and financial performance. These include:

  1. Market Dependence: The company’s revenue is heavily reliant on the success of its CGM systems. Any decline in demand or increased competition could adversely affect its financial performance.
  2. Regulatory Challenges: As a medical device manufacturer, DexCom is subject to stringent regulatory requirements. Delays in product approvals or changes in regulations could impact the company’s operations.
  3. Supply Chain Disruptions: The global supply chain crisis has highlighted the vulnerability of manufacturing and distribution networks. Any disruptions could affect DexCom’s ability to meet customer demand.
  4. Technological Obsolescence: The rapid pace of technological advancements in the healthcare sector poses a risk of obsolescence for DexCom’s products.

Recent Developments

DexCom has made significant strides in recent years, including the launch of the DexCom G7 system, which has received positive feedback for its improved design and performance. The company has also expanded its partnerships with third-party device manufacturers to enhance interoperability and provide users with more comprehensive solutions.

In response to the COVID-19 pandemic, DexCom accelerated its digital transformation efforts, enabling remote patient monitoring and telehealth solutions. These initiatives have positioned the company as a leader in the evolving healthcare landscape.

Investment Considerations

DexCom offers several strengths and risks for potential investors to consider:

Strengths

  • Market Leadership: DexCom is a leader in the CGM market, with a strong brand reputation and a loyal customer base.
  • Innovative Products: The company’s focus on innovation has resulted in a robust product portfolio that meets the needs of diverse user groups.
  • Recurring Revenue Model: DexCom’s subscription-based business model provides a stable and predictable revenue stream.

Risks

  • High Valuation: DexCom’s stock is often considered overvalued, which could limit its upside potential.
  • Regulatory Risks: The company’s reliance on regulatory approvals poses a risk to its product pipeline.
  • Competitive Pressure: Intense competition in the CGM market could impact DexCom’s market share and profitability.

Conclusion

DexCom, Inc. is a pioneering company in the field of continuous glucose monitoring, offering innovative solutions that improve the lives of individuals with diabetes. With a strong focus on innovation, market expansion, and sustainability, DexCom is well-positioned for future growth. However, investors should carefully consider the risks associated with the company’s high valuation and competitive landscape. Overall, DexCom remains a compelling player in the medical technology sector, with significant potential for long-term success.